Peptide YY

Research Papers and Clinical Trials

The research on peptide YY (PYY) encompasses several key areas, though the available evidence is limited and comes from varied study approaches.

Therapeutic Potential and Mechanisms

A 2026 narrative review examined the therapeutic potential of modulating endogenous PYY expression for controlling overweight and obesity (PMID: 42325510). This review synthesized existing knowledge about PYY's role as an appetite-regulating hormone, though specific study details and sample sizes were not provided in the available evidence.

Dietary Interventions and PYY Response

One completed clinical trial (NCT01999504) investigated gut hormone responses, including PYY, after consuming paleolithic-type meals, though the study design, sample size, and results are not detailed in the available information.

A 2026 study published in the Journal of Obesity examined how a healthy diet intervention affected food preferences and eating behaviors (PMID: 42318824). While this study looked at appetite-related outcomes, it found no changes in adipokines or glucose homeostasis, suggesting that dietary interventions may have limited effects on some metabolic parameters.

Clinical Populations and Disease States

Research has explored PYY in specific patient populations. One completed observational study (NCT02385617) examined food intake and gut hormones, including PYY, in patients who underwent upper gastrointestinal surgery for cancer.

A 2026 study in the Orphanet Journal of Rare Diseases investigated the relationship between appetite hormones and body mass index in children with intoxication-type metabolic diseases (PMID: 42316233), though specific findings were not detailed in the available evidence.

Surgical Interventions

One clinical study (NCT05446415) is examining L-cell activity in the small intestine in obese patients with type 2 diabetes who underwent Roux-en-Y gastric bypass (RYGBP), focusing on the biliopancreatic loop's role. The status of this study is unknown.

Pharmaceutical Development

A completed Phase 1 safety and pharmacokinetic study (NCT01515319) evaluated Y242 in adult subjects, though this compound's relationship to PYY and study outcomes are not specified in the available information.

Limitations

The current evidence base is limited, with many studies lacking detailed methodology, sample sizes, or results in the provided information. Most research appears to be in early phases, and the clinical applications of PYY modulation remain under investigation.

Note: This synthesis is based solely on the limited evidence provided and should not be considered comprehensive medical advice. Consult healthcare professionals for personalized treatment decisions.